FDC Ltd
NSE: FDC BSE: 531599
₹363.60
(0.28%)
Mon, 25 May 2026, 06:56 pm
Market Cap59.05B
PE Ratio27.32
Dividend1.38
Health Technology
Pharmaceuticals: Major
24.5KFDC Analysis
dividend
- Dividends after 3 years are expected to be thoroughly covered by earnings (7.7x coverage).
- Dividends per share have fallen over the past 10 years.
- Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
- FDC's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
- FDC's dividend is below the markets top 25% of dividend payers in India (3.08%).
future
- Cash flow for FDC is expected to increase by more than 50% in 2 years time.
- FDC's earnings growth is expected to exceed the India market average.
- FDC's earnings growth is expected to exceed the low risk savings rate of 7.2%.
- FDC's earnings are expected to exceed the low risk growth rate next year.
- FDC is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
- Performance (ROE) is expected to be above the current IN Pharmaceuticals industry average.
- An improvement in FDC's performance (ROE) is expected over the next 3 years.
- FDC's earnings are expected to grow by 19.9% yearly, however this is not considered high growth (20% yearly).
health
- FDC is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- FDC is profitable, therefore cash runway is not a concern.
- FDC is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (50590.2%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 2371.9x debt.
- FDC's cash and other short term assets cover its long term commitments.
- The level of debt compared to net worth has been reduced over the past 5 years (0.2% vs 0% today).
- FDC earns more interest than it pays, coverage of interest payments is not a concern.
- FDC's level of debt (0%) compared to net worth is satisfactory (less than 40%).
- High level of physical assets or inventory.
management
- The tenure for the FDC board of directors is about average.
- Nandan's remuneration is lower than average for companies of similar size in India.
- Nandan's compensation has been consistent with company performance over the past year, both up more than 20%.
- The average tenure for the FDC management team is over 5 years, this suggests they are a seasoned and experienced team.
misc
- FDC is covered by less than 3 analysts.
- FDC has significant price volatility in the past 3 months.
past
- FDC's 1-year earnings growth exceeds its 5-year average (28.4% vs 4.6%)
- FDC's year on year earnings growth rate has been positive over the past 5 years.
- FDC used its assets more efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- FDC's earnings growth has exceeded the IN Pharmaceuticals industry average in the past year (28.4% vs 22.7%).
- FDC's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
- FDC has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
value
- 531599 outperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- 531599 outperformed the Market in India which returned -14.5% over the past year.
- FDC's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- FDC's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- FDC is overvalued based on assets compared to the IN Pharmaceuticals industry average.
- FDC is overvalued based on earnings compared to the IN Pharmaceuticals industry average.
- FDC is overvalued based on earnings compared to the India market.
- BSE:531599 is up 3.3% underperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- BSE:531599 is up 3.3% underperforming the market in India which returned 8% over the past month.